Show simple item record

dc.contributor.authorBaskin, Britahny M.en_US
dc.contributor.authorDwoskin, Linda P.en_US
dc.contributor.authorKantak, Kathleen M.en_US
dc.coverage.spatialUnited Statesen_US
dc.date2015-01-26
dc.date.accessioned2017-11-20T17:07:46Z
dc.date.available2017-11-20T17:07:46Z
dc.date.issued2015-04
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/25643872
dc.identifier.citationBritahny M. Baskin, Linda P. Dwoskin, Kathleen M. Kantak. 2015. "Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder.." Pharmacol Biochem Behav, v. 131, pp. 51 - 56.
dc.identifier.issn1873-5177
dc.identifier.urihttps://hdl.handle.net/2144/25615
dc.description.abstractPast research with the spontaneously hypertensive rat (SHR) model of attention deficit/hyperactivity disorder showed that adolescent methylphenidate treatment enhanced cocaine abuse risk in SHR during adulthood. The acquisition of cocaine self-administration was faster, and cocaine dose-response functions were shifted upward under fixed-ratio and progressive ratio schedules compared to adult SHR that received adolescent vehicle treatment or to control strains that received adolescent methylphenidate treatment. The current study determined if extending treatment beyond adolescence would ameliorate long-term consequences of adolescent methylphenidate treatment on cocaine abuse risk in adult SHR. Treatments (vehicle or 1.5mg/kg/day oral methylphenidate) began on postnatal day 28. Groups of male SHR were treated with vehicle during adolescence and adulthood, with methylphenidate during adolescence and vehicle during adulthood, or with methylphenidate during adolescence and adulthood. The group receiving adolescent-only methylphenidate was switched to vehicle on P56. Cocaine self-administration began on postnatal day 77, and groups receiving methylphenidate during adolescence and adulthood were treated either 1-h before or 1-h after daily sessions. At baseline under a fixed-ratio 1 schedule, cocaine self-administration (2h sessions; 0.3mg/kg unit dose) did not differ among the four treatment groups. Under a progressive ratio schedule (4.5h maximum session length; 0.01-1.0mg/kg unit doses), breakpoints for self-administered cocaine in SHR receiving the adult methylphenidate treatment 1-h pre-session were not different from the vehicle control group. However, compared to the vehicle control group, breakpoints for self-administered cocaine at the 0.3 and 1.0mg/kg unit doses were greater in adult SHR that received adolescent-only methylphenidate or received methylphenidate that was continued into adulthood and administered 1-h post-session. These findings suggest that extending methylphenidate treatment beyond adolescence does not ameliorate explicitly the long-term consequences of adolescent methylphenidate treatment. Pre-session methylphenidate may mask temporarily the detection of an increase in cocaine self-administration following chronic methylphenidate treatment.en_US
dc.description.sponsorshipR01 DA011716 - NIDA NIH HHSen_US
dc.format.extentp. 51-56en_US
dc.languageeng
dc.language.isoen_US
dc.publisherElsevieren_US
dc.relation.ispartofPharmacol Biochem Behav
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAdolescenceen_US
dc.subjectAttention deficit/hyperactivity disorderen_US
dc.subjectCocaineen_US
dc.subjectMethylphenidateen_US
dc.subjectSelf-administrationen_US
dc.subjectSpontaneously hypertensive raten_US
dc.subjectAnimalsen_US
dc.subjectMaleen_US
dc.subjectSpontaneously hypertensive raten_US
dc.subjectScience & technologyen_US
dc.subjectLife sciences & biomedicineen_US
dc.subjectBehavioral sciencesen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectDeficit hyperactivity disorderen_US
dc.subjectMedial prefrontal cortexen_US
dc.subjectLater substance-abuseen_US
dc.subjectDopamine transporteren_US
dc.subjectProgressive-ratioen_US
dc.subjectOral methylphenidateen_US
dc.subjectAtomoxetine treatmentsen_US
dc.subjectGenetic modelen_US
dc.subjectRodent modelen_US
dc.subjectAge factorsen_US
dc.subjectAttention deficit disorder with hyperactivityen_US
dc.subjectCentral nervous system stimulantsen_US
dc.subjectCocaine-related disordersen_US
dc.subjectDisease models, animalen_US
dc.subjectDose-response relationship, drugen_US
dc.subjectRats, inbred SHRen_US
dc.titleMethylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorderen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.pbb.2015.01.019
pubs.elements-sourcepubmeden_US
pubs.notesEmbargo: Not knownen_US
pubs.organisational-groupBoston Universityen_US
pubs.organisational-groupBoston University, College of Arts & Sciencesen_US
pubs.organisational-groupBoston University, College of Arts & Sciences, Department of Psychological & Brain Sciencesen_US
pubs.publication-statusPublisheden_US
dc.identifier.orcid0000-0003-1866-9485 (Kantak, Kathleen M)


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International